Carrie Koenigsfeld1, Morgan Sayler2,3, Hayden L Smith4,5, Kristin Meyer1, Nicholas Lehman1, Craig Logemann6, Michelle Bottenberg1, Ginelle Bryant1, Molly Obermark1. 1. 1 Department of Clinical Sciences, Drake University College of Pharmacy and Health Sciences, Des Moines, IA, USA. 2. 2 Department of Pharmacy Practice and Science, University of Iowa College of Pharmacy, Iowa City, IA, USA. 3. 3 Iowa Lutheran Hospital Family Medicine Residency Program, Des Moines, IA, USA. 4. 4 UnityPoint Health-Des Moines, Des Moines, IA, USA. 5. 5 University of Iowa Carver College of Medicine, Iowa City, IA, USA. 6. 6 UnityPoint Clinic Family Medicine and Urgent Care at Urbandale, Urbandale, IA, USA.
Abstract
PURPOSE: Study goal was to assess the impact of the 2013 American College of Cardiology and the American Heart Association (ACC/AHA) Cholesterol Guidelines on patients in the fourth statin benefit group which included patients aged 40 to 75 years, without diabetes or clinical atherosclerotic cardiovascular disease (ASCVD), and have an ASCVD score ≥7.5%. These patients could benefit from treatment interventions by a pharmacist. METHODS: Patients were identified from electronic health records. A sample of 3503 patients was ascertained from having a lipid panel performed within the 12 months before November 1, 2013. Patients were excluded if we were unable to calculate 10-year ASCVD risk. RESULTS: A total of 3203 patients were included, with 2008 not on statin therapy. Of those, 1507 (75%) had a 10-year ASCVD risk score <7.5% and 501 (25%) had a score > 7.5%. Patient characteristics leading to an increase in risk included advanced age, smoker, male, and hypertension treatment. Of 2008 nonstatin patients, there were 466 (23.2%) who fit criteria for initiation of moderate- or high-intensity statin. CONCLUSION: Widespread adoption of the 2013 ACC/AHA Cholesterol Guidelines will expand prescribing rates of statins. Implementing screening strategies may help identify patients who require treatment in this fourth statin benefit group. A pharmacist can be vital in screening patients, educating patients regarding the need for medication therapy, and monitoring for adherence in these new regimens.
PURPOSE: Study goal was to assess the impact of the 2013 American College of Cardiology and the American Heart Association (ACC/AHA) Cholesterol Guidelines on patients in the fourth statin benefit group which included patients aged 40 to 75 years, without diabetes or clinical atherosclerotic cardiovascular disease (ASCVD), and have an ASCVD score ≥7.5%. These patients could benefit from treatment interventions by a pharmacist. METHODS:Patients were identified from electronic health records. A sample of 3503 patients was ascertained from having a lipid panel performed within the 12 months before November 1, 2013. Patients were excluded if we were unable to calculate 10-year ASCVD risk. RESULTS: A total of 3203 patients were included, with 2008 not on statin therapy. Of those, 1507 (75%) had a 10-year ASCVD risk score <7.5% and 501 (25%) had a score > 7.5%. Patient characteristics leading to an increase in risk included advanced age, smoker, male, and hypertension treatment. Of 2008 nonstatin patients, there were 466 (23.2%) who fit criteria for initiation of moderate- or high-intensity statin. CONCLUSION: Widespread adoption of the 2013 ACC/AHA Cholesterol Guidelines will expand prescribing rates of statins. Implementing screening strategies may help identify patients who require treatment in this fourth statin benefit group. A pharmacist can be vital in screening patients, educating patients regarding the need for medication therapy, and monitoring for adherence in these new regimens.
Authors: Thomas P Power; Xuehua Ke; Zhenxiang Zhao; Nicole Gidaya Bonine; Mark J Cziraky; Michael Grabner; John J Barron; Ralph Quimbo; Burkhard Vangerow; Peter P Toth Journal: Vasc Health Risk Manag Date: 2018-02-05